Cutler Group LP Relmada Therapeutics, Inc. Put Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2023 May 01, 2023	SELL	$2.24 - $4.76 $33,600 - $71,400	-15,000 Reduced 96.15%	600 $3,000
Q4 2022 Feb 07, 2023	BUY	$2.17 - $35.84 $25,172 - $415,744	11,600 Added 290.0%	15,600 $26,000
Q3 2022 Oct 25, 2022	SELL	$18.3 - $37.02 $146,400 - $296,160	-8,000 Reduced 66.67%	4,000 $26,000
Q2 2022 Aug 04, 2022	SELL	$16.5 - $30.34 $300,300 - $552,188	-18,200 Reduced 60.26%	12,000 $9,000
Q1 2022 Apr 14, 2022	BUY	$16.72 - $26.99 $503,271 - $812,399	30,100 Added 30100.0%	30,200 $43,000
Q4 2021 Jan 18, 2022	SELL	$16.93 - $26.82 $49,097 - $77,778	-2,900 Reduced 96.67%	100 $0
Q3 2021 Oct 26, 2021	BUY	$21.86 - $34.77 $15,302 - $24,339	700 Added 30.43%	3,000 $6,000
Q4 2020 Jan 21, 2021	BUY	$29.88 - $39.8 $47,808 - $63,679	1,600 Added 228.57%	2,300 $14,000
Q3 2020 Oct 27, 2020	SELL	$34.42 - $43.78 $10,326 - $13,134	-300 Reduced 30.0%	700 $8,000
Q2 2020 Jul 22, 2020	BUY	$31.59 - $49.98 $15,795 - $24,990	500 Added 100.0%	1,000 $3,000
Q4 2019 Feb 06, 2020	BUY	$10.1 - $47.18 $5,050 - $23,590	500 New	500 $1,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.